Anti‑Transferrin Receptor Antibodies and Uses Thereof

Patent Title: Anti‑Transferrin Receptor Antibodies and Uses Thereof
Application Number: PCT/US2025/021874
Publication Number: WO/2025/207959
Filing Date: March 27, 2025
Publication Date: October 2, 2025
Applicant/Assignee: Biogen MA Inc. (Cambridge, Massachusetts, USA)

What This Patent Covers

This international patent application describes antibodies that specifically bind to the transferrin receptor (TfR) and their therapeutic applications:

Anti‑Transferrin Receptor Antibodies: The inventors claim novel antibodies that recognize and bind TfR with high specificity. TfR is a cell surface receptor involved in iron transport and highly expressed on the blood–brain barrier (BBB).
Brain Delivery Platform: Because the transferrin receptor is widely explored as a “shuttle” mechanism to ferry large molecules across the BBB, these antibodies (or antibody‑based constructs) are likely intended to enhance delivery of therapeutic payloads (e.g., enzymes, biologics, or small molecules) into the central nervous system (CNS).
Therapeutic Uses: The patent application includes uses of these antibodies for treating neurological diseases that are difficult to address with conventional drugs due to BBB impermeability. This could encompass neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s) and other CNS conditions.
Methods of Treatment: Claims likely extend to pharmaceutical compositions containing the anti‑TfR antibodies and methods of administering them, alone or as conjugates, to patients in need of enhanced CNS drug delivery.

Why This Patent Is Important

1) Addresses a Major Unmet Need in Neurology
CNS diseases (Alzheimer’s, Parkinson’s, ALS, etc.) represent multi‑billion‑dollar markets, but drug development has been hampered by the blood–brain barrier. Technologies that safely and effectively deliver therapeutics into the brain could unlock many high‑value treatments.

2) Platform Potential Beyond One Drug
Anti‑TfR antibody technology is not limited to a single disease — it can serve as a platform for delivering diverse therapeutic cargos (ADC‑like conjugates, enzymes, neuroprotective agents, gene therapy vectors) into the CNS. That multiplies its commercial value.

3) Competitive Edge in CNS Biologics
Biogen’s strategic focus on neurodegenerative diseases (e.g., with Alzheimer’s therapies like LEQEMBI) makes a strong intellectual property position around CNS delivery especially valuable for future pipeline assets and partnerships.

BioTech IP Review